FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

Adverse Event Reporting   - Biological Product Deviation Reporting   - MedWatch   - Transfusion / Donation Related Fatalities   - Vaccine Adverse Event Reporting System All About Vaccines for Kids Clin Investigator Info Counterfeit Initiative Countering Bioterrorism FAQs   - General   - Blood   - Vaccines FDA Patient Safety News Healthcare Letters Keeping Blood Transfusions Safe NIH Clinical Trials Database NLM MEDLINEplus Health Information Product Approvals Product Labeling Product Shortages Recalls / Withdrawals Safety Information Vaccines Provide Effective Protection Violative Advert / Promo Letters Warning Letters   - Other Compliance Actions FDA Information   - Consumers   - Consumer Magazine   - Health Professionals   - Patients

CBER is responsible for ensuring the safety and efficacy of blood and blood products, vaccines, allergenics, and biological therapeutics. CBER's regulation of biological products has expanded in recent years to include a wide variety of new products such as biotechnology products, somatic cell therapy and gene therapy, and banked human tissues. If you have questions or are unable to find the information you need, please contact: Center for Biologics Evaluation and Research Office of Communication, Training & Manufacturers Assistance 800-835-4709 or 301-827-1800 octma@cber.fda.gov   Transfer of Therapeutic Products to CDER   FDA Advances Consumer Health and Safety in 2003

Updated August 26, 2004

CBER Home Page | CBER A-Z Index | CBER Search | Contact CBER FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page FDA / Center for Biologics Evaluation and Research